385 related articles for article (PubMed ID: 18779748)
1. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
4. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
5. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
6. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
[TBL] [Abstract][Full Text] [Related]
7. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
8. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
9. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
Zhang N; Sadun RE; Arias RS; Flanagan ML; Sachsman SM; Nien YC; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2007 May; 13(9):2758-67. PubMed ID: 17460060
[TBL] [Abstract][Full Text] [Related]
10. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
11. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
12. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
13. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
14. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
15. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
16. Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell.
Wu C; Guo H; Wang Y; Gao Y; Zhu Z; Du Z
Cell Immunol; 2011; 271(1):118-23. PubMed ID: 21745658
[TBL] [Abstract][Full Text] [Related]
17. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
18. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.
Guo H; Jiang W; Liu W; Gao Y; Yang M; Zhou Y; Wang J; Qi J; Cheng X; Zhu Z; Yang C; Xiong D
Cell Immunol; 2008 Feb; 251(2):102-8. PubMed ID: 18482719
[TBL] [Abstract][Full Text] [Related]
19. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.
Liu GZ; Gomes AC; Putheti P; Karrenbauer V; Kostulas K; Press R; Hillert J; Hjelmström P; Gao XG
Scand J Immunol; 2006 Oct; 64(4):412-9. PubMed ID: 16970683
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]